Study of BMS-986158 in Subjects With Select Advanced Cancers
Status: Active
Description
The purpose of this study is to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of BMS-986158 in subjects with select advanced cancers
Eligibility Criteria
Inclusion Criteria
- Must have select advanced cancers with specific genetic profiles
- Must have received appropriate standard of care
- At least one measurable lesion at baseline
- Expected to have life expectancy of at least 3 months
- Eastern Cooperative Oncology Group (ECOG) of 0 to 1
Exclusion Criteria
- Concomitant second malignancies
- Uncontrolled or significant cardiovascular disease
- Inadequate bone marrow function
- Chronic gastrointestinal illness
- Prior treatment with Bromodomain and Extra-Terminal (BET) inhibitor
Locations & Contacts
California
Duarte
City of Hope Comprehensive Cancer Center
Status: Active
Contact: Mihaela C. Cristea
Phone: 626-359-8111
Email: becomingapatient@coh.org
Status: Active
Contact: Mihaela C. Cristea
Phone: 626-359-8111
Email: becomingapatient@coh.org
Colorado
Aurora
University of Colorado Hospital
Status: Active
Name Not Available
Status: Active
Name Not Available
Massachusetts
Boston
Brigham and Women's Hospital
Status: Active
Name Not Available
Status: Active
Name Not Available
Dana-Farber Cancer Institute
Status: Active
Name Not Available
Status: Active
Name Not Available
Missouri
Saint Louis
Siteman Cancer Center at Washington University
Status: In review
Name Not Available
Status: In review
Name Not Available
Oregon
Portland
OHSU Knight Cancer Institute
Status: Active
Name Not Available
Status: Active
Name Not Available
Trial Phase & Type
Trial Phase
Trial Type
Treatment
Lead Organization
Lead Organization
Bristol-Myers Squibb